ʻO ke kanaka CYP2C9 a me VKORC1 Gene Polymorphism

ʻO Warfarin kahi anticoagulant waha i hoʻohana mau ʻia i ka hoʻomaʻamaʻa lapaʻau i kēia manawa, i manaʻo nui ʻia no ka pale ʻana a me ka mālama ʻana i nā maʻi thromboembolic.Eia nō naʻe, ʻokoʻa ka warfarin ma waena o nā lāhui a me nā kānaka like ʻole.Ua hōʻike ʻia nā helu helu hiki ke ʻoi aku ka ʻokoʻa o ka maʻa paʻa i nā poʻe like ʻole ma mua o 20 mau manawa.Loaʻa ka hopena maikaʻi ʻole i ke koko ma 15.2% o nā mea maʻi e lawe ana i ka warfarin i kēlā me kēia makahiki, kahi o 3.5% e hoʻomohala i ke koko make.Ua hōʻike ʻia nā haʻawina Pharmacogenomic ʻo ka polymorphism genetic o ka enzyme target VKORC1 a me ka metabolic enzyme CYP2C9 o warfarin he mea nui e pili ana i ka ʻokoʻa o ka nui o ka warfarin.ʻO Warfarin kahi mea paʻa paʻa o ka vitamina K epoxide reductase (VKORC1), a no laila ke kāohi nei i ka synthesis factor clotting e pili ana i ka vitamina K a hāʻawi i ka anticoagulation.Ua hōʻike ʻia kahi helu nui o nā haʻawina ʻo ka gene polymorphism o ka mea hoʻolaha VKORC1 ka mea nui loa e pili ana i ka lāhui a me nā ʻokoʻa o kēlā me kēia kanaka i ka nui o ka warfarin.Hoʻopili ʻia ʻo Warfarin e CYP2C9, a ʻoi aku ka lohi o kāna mau mutants i ka metabolism o warfarin.ʻO ka poʻe e hoʻohana ana i ka warfarin, ʻoi aku ka nui o ka pilikia (ʻelua a ʻekolu mau manawa kiʻekiʻe) o ke koko i ka wā mua o ka hoʻohana ʻana.